A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
A phase 2/3 trial of Ipilimumab, Nivolumab in melanoma and uveal melanoma, run by Replimune, Inc., now recruiting.
Overview
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma is a phase 2/3 interventional study registered as NCT06581406 by Replimune, Inc., with 280 participants planned, started 2024-12-17 and due to reach its primary completion in 2030-01. Interventions recorded: RP2, Ipilimumab, Nivolumab. Conditions listed: Metastatic Uveal Melanoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialStudy of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
- TrialDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
Shares Uveal melanoma, Ipilimumab, Melanoma.
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialA Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
Shares Ipilimumab, Nivolumab, Melanoma.
- PersonJennifer A. Wargo
Shares Ipilimumab, Nivolumab, Melanoma.
- TrialIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Shares Uveal melanoma, Ipilimumab, Nivolumab, Melanoma.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.